Cover Image
市場調查報告書

Thrombotargets Corporation:產品平台分析

Thrombotargets Corporation - Product Pipeline Review - 2014

出版商 Global Markets Direct 商品編碼 203744
出版日期 內容資訊 英文 23 Pages
訂單完成後即時交付
價格
Back to Top
Thrombotargets Corporation:產品平台分析 Thrombotargets Corporation - Product Pipeline Review - 2014
出版日期: 2014年09月15日 內容資訊: 英文 23 Pages
簡介

Thrombotargets Corporation 是致力於研發治療遺傳性/後天性出血性疾病及血栓症的藥物候補之生物科技企業。該公司提供止血藥,抗凝固劑,診斷藥,血小板抑制劑,抗氧化劑等產品。此外也致力於開發基於遺傳基因重組,分子生物學,小分子藥技術之進步的新藥。

本報告提供Thrombotargets Corporation 的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

Thrombotargets Corporation 基本資料

  • Thrombotargets Corporation 概要
  • 主要資訊
  • 企業資料

Thrombotargets Corporation:R&D概要

  • 主要的治療範圍

Thrombotargets Corporation:評估

  • 各開發階段的開發中產品
  • 單劑產品

Thrombotargets Corporation:開發中產品概況

  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
  • 初期階段產品開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

Thrombotargets Corporation:藥物簡介

  • TT-173
  • TT-105
  • TT-111
  • TT-112
  • TT-120

Thrombotargets Corporation:開發平台分析

  • 各給藥途徑
  • 各分子類型

Thrombotargets Corporation:最近的開發平台趨勢

Thrombotargets Corporation:暫停中的計劃

Thrombotargets Corporation:總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC06365CDB

Summary

Global Markets Direct's, 'Thrombotargets Corporation - Product Pipeline Review - 2014', provides an overview of the Thrombotargets Corporation's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Thrombotargets Corporation's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Thrombotargets Corporation including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Thrombotargets Corporation's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Thrombotargets Corporation's pipeline products

Reasons to buy

  • Evaluate Thrombotargets Corporation's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Thrombotargets Corporation in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Thrombotargets Corporation's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Thrombotargets Corporation and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Thrombotargets Corporation
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Thrombotargets Corporation and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Thrombotargets Corporation Snapshot
    • Thrombotargets Corporation Overview
    • Key Information
    • Key Facts
  • Thrombotargets Corporation - Research and Development Overview
    • Key Therapeutic Areas
  • Thrombotargets Corporation - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Thrombotargets Corporation - Pipeline Products Glance
    • Thrombotargets Corporation - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
    • Thrombotargets Corporation - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Thrombotargets Corporation - Drug Profiles
    • TT-173
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TT-105
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TT-111
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TT-112
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TT-120
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Thrombotargets Corporation - Pipeline Analysis
    • Thrombotargets Corporation - Pipeline Products by Route of Administration
    • Thrombotargets Corporation - Pipeline Products by Molecule Type
  • Thrombotargets Corporation - Recent Pipeline Updates
  • Thrombotargets Corporation - Dormant Projects
  • Thrombotargets Corporation - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Thrombotargets Corporation, Key Information
  • Thrombotargets Corporation, Key Facts
  • Thrombotargets Corporation - Pipeline by Indication, 2014
  • Thrombotargets Corporation - Pipeline by Stage of Development, 2014
  • Thrombotargets Corporation - Monotherapy Products in Pipeline, 2014
  • Thrombotargets Corporation - Phase II, 2014
  • Thrombotargets Corporation - Preclinical, 2014
  • Thrombotargets Corporation - Discovery, 2014
  • Thrombotargets Corporation - Pipeline by Route of Administration, 2014
  • Thrombotargets Corporation - Pipeline by Molecule Type, 2014
  • Thrombotargets Corporation - Recent Pipeline Updates, 2014
  • Thrombotargets Corporation - Dormant Developmental Projects,2014
  • Thrombotargets Corporation, Other Locations

List of Figures

  • Thrombotargets Corporation - Pipeline by Top 10 Indication, 2014
  • Thrombotargets Corporation - Pipeline by Stage of Development, 2014
  • Thrombotargets Corporation - Monotherapy Products in Pipeline, 2014
  • Thrombotargets Corporation - Pipeline by Top 10 Molecule Type, 2014
Back to Top